3,246
Views
37
CrossRef citations to date
0
Altmetric
Clinical Study

An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN

, , , , ORCID Icon, & show all
Pages 306-313 | Received 07 Nov 2017, Accepted 15 Mar 2018, Published online: 06 Apr 2018

References

  • Beck LH Jr, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010;77:765–770.
  • Beck LH, Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.
  • Tomas NM, Beck LH, Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277–2287.
  • Iwakura T, Ohashi N, Kato A, et al. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One. 2015;10:e0138841.
  • Hoxha E, Beck LH Jr, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2016;28:520–531.
  • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
  • Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2017 [cited 2017 Dec 15]. DOI:10.1038/modpathol.2017.163
  • Liyin W. Significance of M-type phospholipase A2 receptor and type 1 thrombospondin domain 7A in adult idiopathic membranous nephropathy. Chin J Nephrol. 2016;32:561–567.
  • Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28:348–358.
  • Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-i domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:1642–1651.
  • Jianing L. Diagnostic study of serum anti-M type phospholipase A2 receptor (PLA2R) antibody negative idiopathic membranous nephropathy. Dissertation [Translation]; 2015.
  • Hayashi NMY, Imura J, Fujimoto K, et al. Prevalence of M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7a (THSD7A) in the glomerular deposits of Japanese membranous nephropathy. 53rd ERA-EDTA congress Vienna Austria [Abstract]; 2015.
  • Didi H. The value of thrombospondin type 1 domain–containing 7A and phospholipase A2 receptor in the diagnosis of membranous nephropathy. 2016 annual congress of Chinese society of nephrology [Translation]; 2016.
  • Ge Y, Jin B, Zeng C, et al. PLA2R antibodies and PLA2R and THSD7A glomerular deposits in psoriasis patients with membranous nephropathy. Nephrol Dial Transplant. 2016;31:i430.
  • Kuo MW, Wang CH, Wu HC, et al. Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis. PLoS One. 2011;6:e29000.
  • Wang CH, Su PT, Du XY, et al. Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation. J Cell Physiol. 2010;222:685–694.
  • Tomas NM. Autoantibodies against thrombospondin type 1 domain–containing 7A induce membranous nephropathy; 2016.
  • Hoxha E, Wiech T, Stahl PR, et al. A mechanism for cancer-associated membranous nephropathy. N Engl J Med. 2016;374:1995–1996.